Suppr超能文献

熊去氧胆酸对胆结石患者和正常受试者胆囊收缩及胆囊收缩素释放的影响。

Effects of ursodeoxycholic acid on gallbladder contraction and cholecystokinin release in gallstone patients and normal subjects.

作者信息

van Erpecum K J, van Berge Henegouwen G P, Stolk M F, Hopman W P, Jansen J B, Lamers C B

机构信息

Department of Gastroenterology, University Hospital Utrecht, The Netherlands.

出版信息

Gastroenterology. 1990 Sep;99(3):836-42. doi: 10.1016/0016-5085(90)90977-9.

Abstract

It has been previously suggested that treatment with ursodeoxycholic acid leads to decreased gallbladder emptying. The proposed mechanism is decreased release of cholecystokinin through negative feedback control by an increased amount of intraduodenal bile acids. In the present study we examined cholecystokinin release and gallbladder contraction after oral administration of a commercial fatty meal (Sorbitract; Dagra, Diemen, The Netherlands) using ultrasonography in eight normal subjects and eight gallstone patients before and after 1 and 4 weeks of treatment with ursodeoxycholic acid (10 mg kg-1.day-1). Fasting gallbladder volume increased in 15 of 16 subjects during treatment (P less than 0.01). Minimal volume did not change. Therefore, both absolute and relative gallbladder emptying increased during therapy. Maximal decrement of gallbladder volume in milliliters and percentage as well as integrated gallbladder contraction during 90 minutes in milliliters and percentage were significantly increased after 1 and 4 weeks of treatment with ursodeoxycholic acid when compared with data before therapy. Gallstone patients tended to have larger fasting and residual gallbladder volumes than normal subjects, whereas parameters for the amount of bile expelled (maximal decrement of gallbladder volume and integrated gallbladder contraction in milliliters and percentage) did not differ. Release of cholecystokinin did not change during treatment and did not differ significantly between patients and normal subjects. Mean relative percentage of ursodeoxycholic acid in bile during treatment in 13 subjects consenting to have duodenal intubation was 47% (range 31%-60%). Changes of fasting gallbladder volume after institution of bile acid treatment correlated significantly (r = 0.74, P less than 0.01) with changes of cholesterol saturation index but not with relative percentage of ursodeoxycholic acid in bile. This study indicates that gallbladder emptying does not decrease during treatment with ursodeoxycholic acid. Moreover, there is no evidence of decreased cholecystokinin release.

摘要

此前有观点认为,用熊去氧胆酸治疗会导致胆囊排空减少。提出的机制是十二指肠内胆汁酸量增加通过负反馈控制使胆囊收缩素释放减少。在本研究中,我们在8名正常受试者和8名胆结石患者口服市售脂肪餐(Sorbitract;荷兰迪门的Dagra公司)前后,使用超声检查了熊去氧胆酸(10毫克/千克·天)治疗1周和4周前后胆囊收缩素的释放及胆囊收缩情况。治疗期间,16名受试者中有15名空腹胆囊体积增加(P<0.01)。最小体积未改变。因此,治疗期间绝对和相对胆囊排空均增加。与治疗前数据相比,熊去氧胆酸治疗1周和4周后,胆囊体积以毫升为单位的最大减少量、百分比以及90分钟内胆囊收缩总量以毫升为单位和百分比均显著增加。胆结石患者的空腹和残余胆囊体积往往比正常受试者大,而胆汁排出量参数(胆囊体积最大减少量和胆囊收缩总量以毫升为单位和百分比)并无差异。治疗期间胆囊收缩素的释放未改变,患者与正常受试者之间也无显著差异。13名同意进行十二指肠插管的受试者治疗期间胆汁中熊去氧胆酸的平均相对百分比为47%(范围31%-60%)。胆汁酸治疗开始后空腹胆囊体积的变化与胆固醇饱和指数的变化显著相关(r = 0.74,P<0.01),但与胆汁中熊去氧胆酸的相对百分比无关。本研究表明,熊去氧胆酸治疗期间胆囊排空并未减少。此外,没有证据表明胆囊收缩素释放减少。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验